Oral ANAVEX 2-73: Completed Phase IIa enrollment

Anavex completed enrollment of 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial to evaluate ANAVEX 2-73. In part A of the trial, patients are receiving a 30...